{"id":1616,"date":"2024-02-07T11:27:21","date_gmt":"2024-02-07T10:27:21","guid":{"rendered":"https:\/\/xinnate.com\/?p=1616"},"modified":"2024-03-18T16:32:47","modified_gmt":"2024-03-18T15:32:47","slug":"xinnate-secures-100-million-sek-in-financing-and-applies-for-a-patent-for-the-treatment-of-epidermolysis-bullosa","status":"publish","type":"post","link":"https:\/\/xinnate.com\/xinnate-secures-100-million-sek-in-financing-and-applies-for-a-patent-for-the-treatment-of-epidermolysis-bullosa\/","title":{"rendered":"Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa"},"content":{"rendered":"

Lund, Sweden, February 7, 2024<\/p>\n

PRESS RELEASE<\/strong><\/p>\n

\"\"
Helene Hartman, CEO, Xinnate<\/figcaption><\/figure>\n

Xinnate conducted a new share issue of 100 million SEK from private investors last year. The funding enables an upcoming phase-2 study for the company’s first drug\u2014a gel for topical treatment of dysfunctional healing in wounds or inflammatory skin conditions. A phase-1 study in three parts is currently underway, including one part with patients suffering from the rare and severe disease Epidermolysis Bullosa. Planning for a multi-site phase-2 study with EB patients is ongoing.<\/p>\n

\u2013 It is incredibly powerful that we can support the patent application with existing results from our clinical study. We aim to develop a drug that reduces harmful inflammation, improves the healing process, and reduces the risk of serious complications, says Helene Hartman, CEO of Xinnate.<\/p>\n

 <\/p>\n

Read full press release here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Lund, Sweden, February 7, 2024 PRESS RELEASE Xinnate conducted a new share issue of 100 million SEK from private investors […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/posts\/1616"}],"collection":[{"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/comments?post=1616"}],"version-history":[{"count":3,"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/posts\/1616\/revisions"}],"predecessor-version":[{"id":1621,"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/posts\/1616\/revisions\/1621"}],"wp:attachment":[{"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/media?parent=1616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/categories?post=1616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xinnate.com\/wp-json\/wp\/v2\/tags?post=1616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}